Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zhidong, Pei"'
Autor:
Jifang Gong, Junning Cao, Qingyuan Zhang, Nong Xu, Yanqiu Zhao, Baocai Xing, Zhanhui Miao, Yilong Wu, Hongming Pan, Quanli Gao, Xingya Li, Baorui Liu, Wei Li, Zhidong Pei, Hongqiang Xia, Qinzhou Qi, Hangjun Dai, Qingmei Shi, Jianxin Yang, Jin Li, Lin Shen
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1897-1908
Background This first-in-human phase 1 trial is to evaluate the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab, a full-length, fully human anti-PD-L1 monoclonal antibody, in Chinese patients with advanced malignancies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3546384a1f6680ae0fb92dc78fcc294a
https://doi.org/10.1007/s00262-021-03102-3
https://doi.org/10.1007/s00262-021-03102-3
Autor:
Xing Sun, Guangyu An, Jianying Zhou, Yanqiu Zhao, Mengzhao Wang, Tao Sun, Cuiying Zhang, Yiping Zhang, Gongyan Chen, Lan Yang, Jian Fang, Yong Song, Shegan Gao, Shun Lu, Shiying Yu, Zhongyao Jia, Conghua Xie, Yunpeng Liu, Qitao Yu, Huiping Wan, Ying Yuan, Meiqi Shi, Yi Geng, Xiaodong Mei, Kejing Ying, Jinliang Wang, Baolan Li, Lijun Wang, Biyong Ren, Guosheng Feng, Bangwei Cao, S. Ma, Yanxia Ji, Jiuwei Cui, Zijun Liao, Jie Yu, Bin Wu, Hui Zhou, Huaqing Wang, Linian Huang, Mu Hu, Li Zhang, Nong Yang, Yunpeng Yang, Zhidong Pei, Ying Cheng
Publikováno v:
Translational Lung Cancer Research. 8:989-999
BACKGROUND: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c7c193fbe786e18aaa2fdaa1745a08
https://doi.org/10.21037/tlcr.2019.12.23
https://doi.org/10.21037/tlcr.2019.12.23
Publikováno v:
Esophagus : official journal of the Japan Esophageal Society. 18(2)
Esophageal cancer (EC) ranks the eighth in morbidity and the sixth in mortality around the whole world, which is an aggressive malignancy. To authenticate potential therapeutic targets for EC is therefore imperative. Although miR-301b might display c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b14318421093e78eb7df728c71cf1063
https://pubmed.ncbi.nlm.nih.gov/32737801
https://pubmed.ncbi.nlm.nih.gov/32737801
Autor:
Lin Shen, Yi-Long Wu, Quanli Gao, Teddy Xia, Qingyuan Zhang, Zhanhui Miao, Hangjun Dai, Zhidong Pei, Rong Guo, Qing Zhou, Yanqiu Zhao, Nong Xu, Jianxin Yang, Jingru Wang
Publikováno v:
Journal of Clinical Oncology. 38:e21687-e21687
e21687 Background: Immuno-oncology (IO) monotherapy or combination with platinum-based chemo is the current standard of care for pts with PD-L1 expression ≥ 50% and EGFR, ALK, ROS1, BRAF negative advanced NSCLC in China. CS1001-101 phase Ib study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::899092dc490762e136a54b2f40a80bc1
https://doi.org/10.1200/jco.2020.38.15_suppl.e21687
https://doi.org/10.1200/jco.2020.38.15_suppl.e21687